COMBINACION DE AL MENOS DOS AGENTES ANTIVIRALES DE ACCION DIRECTA Y RIBAVIRINA PERO NO INTERFERON, PARA USO EN EL TRATAMIENTODEL VHC

摘要

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.